Cofinimmo Resultados de beneficios anteriores
Pasado controles de criterios 4/6
Los beneficios de Cofinimmo han disminuido a una tasa media anual de -21%, mientras que en la industria Health Care REITs los beneficios disminuyeron en un 0.4% anualmente. Los ingresos han ido creciendo a una tasa media de 4.5% al año. La rentabilidad financiera de Cofinimmo es de 5.7%, y sus márgenes netos son de 52.9%.
Información clave
-20.99%
Tasa de crecimiento de los beneficios
-26.47%
Tasa de crecimiento del BPA
| Crecimiento de la industria Health Care REITs | 0.61% |
| Tasa de crecimiento de los ingresos | 4.46% |
| Rentabilidad financiera | 5.67% |
| Margen neto | 52.91% |
| Próxima actualización de resultados | 23 Jul 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
COFB: Aedifica Merger Progress And Index Exit Will Shape Steady Outlook
Analysts have slightly lifted their fair value estimate for Cofinimmo, increasing the price target from €86.17 to €87.39 as they factor in updated assumptions for the discount rate, revenue trends, profit margin and future P/E. What's in the News Aedifica NV/SA has agreed to acquire the remaining 20.41% stake in Cofinimmo SA for approximately €650 million.COFB: Aedifica Merger Path And Index Removal Will Shape Balanced Outlook
Analysts have kept their Cofinimmo price target steady at €86.17, citing only small adjustments to the discount rate, revenue growth assumptions, and profit margin forecasts. Their long-term view remains broadly unchanged.COFB: Index Removal And 2026 Meeting Will Shape Balanced Risk Profile
Analysts have kept their Cofinimmo price target broadly steady at about €86.17, with the latest update reflecting slightly adjusted assumptions on discount rate, revenue growth and profit margin that leave the implied P/E multiple close to prior levels. What's in the News Cofinimmo SA is recorded as having been removed as an index constituent, which may affect how index funds and ETFs with rules-based mandates treat the stock (Key Developments).COFB: Index Exit And Governance Meeting Will Frame Balanced Risk Reward
Analysts have kept their price target for Cofinimmo broadly steady at €86.17. This reflects only marginal tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in their view of the shares.COFB: Buy Upgrade And Margin Confidence Will Shape Future Risk Reward
Analysts have lifted their price target on Cofinimmo to €86.17 from €86.17. The recent upgrade to Buy supports a slightly more constructive view on its margin profile and long term earnings multiple.COFB: Buy Upgrade And Fair Value View Will Frame Future Risk Reward
Analysts have nudged their price target on Cofinimmo higher to €86.17, reflecting updated assumptions on discount rates, a move to modest revenue growth, a slightly lower profit margin, and a higher forward P/E, alongside a recent upgrade to Buy from a major research house. Analyst Commentary Recent research adjustments give you a clearer view of how the market is framing Cofinimmo at the current price target of €86.17 and the revised assumptions on growth, margins, and P/E.COFB: Buy Upgrade And Refined Assumptions Will Shape Future Risk Reward Balance
Analysts have nudged their fair value estimate for Cofinimmo higher from about €83.72 to around €86.17, citing updated assumptions on discount rates, revenue trends and future P/E, in line with the recent Buy rating upgrade from Kepler Cheuvreux. Analyst Commentary Bullish Takeaways Bullish analysts see the fair value increase from about €83.72 to around €86.17 as support for the recent rating upgrade, suggesting the current share price offers some valuation headroom relative to their assumptions.COFB: Rating Upgrade And Refined Assumptions Will Shape Future Risk Reward Balance
Analysts have modestly adjusted their price targets on Cofinimmo, reflecting slight tweaks to discount rate, revenue growth and profit margin assumptions. Some now see greater upside potential following recent positive research updates and upgrades to Buy.COFB: Rating Upgrade And Refined Assumptions Will Support Fair Value
Analysts have nudged their fair value target for Cofinimmo higher from €81.77 to €83.72, citing updated assumptions around discount rates, profit margins and future P/E, alongside recent positive Street research support. Analyst Commentary Recent Street research has taken a more constructive stance on Cofinimmo, reflected in the higher fair value target of €83.72.COFB: Rating Upgrade And Stable Cash Flows Will Support Fair Value
Analysts have nudged their fair value estimate for Cofinimmo from €81.41 to €81.77, citing a modestly lower discount rate and slightly refined revenue, margin and future P/E assumptions following recent positive Street research. Analyst Commentary Street research has turned more constructive on Cofinimmo, with some analysts moving to a more positive stance and the fair value estimate edging up to €81.77.COFB: Stable Metrics Will Support Fair Value As Risk Perception Slightly Eases
Analysts have trimmed their price target on Cofinimmo slightly to €81.41 from €81.86. This reflects a modestly lower projected future price to earnings multiple and a marginally reduced discount rate in their valuation models.COFB: Stable Metrics Will Support Fair Value Amid Slight Profitability Improvement
Narrative Update on Cofinimmo Analysts have modestly raised their price target on Cofinimmo to EUR 81.86, citing a slightly lower implied discount rate and improved projected profit margins, while growth expectations and valuation multiples remain largely unchanged. Valuation Changes Fair Value: Unchanged at €81.86 per share, indicating a stable intrinsic value estimate.COFB: Financial Metrics Consistency Will Support Stable Fair Value Outlook
Analysts have maintained their fair value estimate for Cofinimmo at €81.86, citing consistent forecasted financial metrics and only minimal updates to underlying assumptions. Valuation Changes Fair Value Estimate remains unchanged at €81.86.COFB: Revenue and Profit Margin Trends Will Shape Fair Value Outlook
Analysts have slightly increased their price target for Cofinimmo from €80.92 to €81.86. They cite improved revenue growth projections and a marginally lower discount rate as key factors behind the adjustment.Healthcare Real Estate Shift Will Yield Lasting Value
Strategic focus on healthcare real estate and divesting non-core areas aims to improve revenue and optimize net margins.Shareholders Of Cofinimmo (EBR:COFB) Must Be Happy With Their 64% Return
Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...Desglose de ingresos y gastos
Cómo gana y gasta dinero Cofinimmo. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 383 | 203 | 11 | 0 |
| 31 Dec 25 | 382 | 213 | 14 | 0 |
| 30 Sep 25 | 390 | 192 | 12 | 0 |
| 30 Jun 25 | 391 | 134 | 13 | 0 |
| 31 Mar 25 | 392 | 111 | 14 | 0 |
| 31 Dec 24 | 392 | 64 | 13 | 0 |
| 30 Sep 24 | 392 | -52 | 12 | 0 |
| 30 Jun 24 | 392 | -41 | 13 | 0 |
| 31 Mar 24 | 391 | -55 | 14 | 0 |
| 31 Dec 23 | 389 | -55 | 14 | 0 |
| 30 Sep 23 | 379 | 49 | 16 | 0 |
| 30 Jun 23 | 379 | 185 | 15 | 0 |
| 31 Mar 23 | 373 | 333 | 14 | 0 |
| 31 Dec 22 | 368 | 483 | 14 | 0 |
| 30 Sep 22 | 367 | 565 | 16 | 0 |
| 30 Jun 22 | 357 | 489 | 14 | 0 |
| 31 Mar 22 | 351 | 382 | 13 | 0 |
| 31 Dec 21 | 343 | 260 | 12 | 0 |
| 30 Sep 21 | 328 | 189 | 15 | 0 |
| 30 Jun 21 | 312 | 155 | 13 | 0 |
| 31 Mar 21 | 276 | 122 | 18 | 0 |
| 31 Dec 20 | 293 | 119 | 10 | 0 |
| 30 Sep 20 | 296 | 170 | 12 | 0 |
| 30 Jun 20 | 266 | 193 | 22 | 0 |
| 31 Mar 20 | 292 | 222 | 9 | 0 |
| 31 Dec 19 | 285 | 205 | 9 | 0 |
| 30 Sep 19 | 241 | 134 | 24 | 0 |
| 30 Jun 19 | 270 | 119 | 8 | 0 |
| 31 Mar 19 | 259 | 105 | 8 | 0 |
| 31 Dec 18 | 263 | 146 | 8 | 0 |
| 30 Sep 18 | 260 | 186 | 8 | 0 |
| 30 Jun 18 | 258 | 170 | 8 | 0 |
| 31 Mar 18 | 264 | 166 | 8 | 0 |
| 31 Dec 17 | 263 | 137 | 8 | 0 |
| 30 Sep 17 | 267 | 121 | 8 | 0 |
| 30 Jun 17 | 267 | 128 | 8 | 0 |
| 31 Mar 17 | 275 | 134 | 8 | 0 |
| 31 Dec 16 | 257 | 97 | 9 | 0 |
| 30 Sep 16 | 253 | 100 | 9 | 0 |
| 30 Jun 16 | 255 | 82 | 9 | 0 |
| 31 Mar 16 | 249 | 110 | 9 | 0 |
| 31 Dec 15 | 255 | 104 | 8 | 0 |
| 30 Sep 15 | 260 | 76 | 8 | 0 |
| 30 Jun 15 | 262 | 66 | 8 | 0 |
Ingresos de calidad: COFB tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (52.9%) de COFB son superiores a los del año pasado (28.3%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de COFB han disminuido en un 21% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de COFB en el último año (83.2%) supera su media de 5 años (-21% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de COFB en el último año (83.2%) superó al de la industria Health Care REITs 77.8%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de COFB (5.7%) se considera baja.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/15 15:28 |
| Precio de las acciones al final del día | 2026/06/12 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cofinimmo SA está cubierta por 19 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Celine Huynh | Barclays |
| Kai Klose | Berenberg |
| Robert Jones | BNP Paribas |